Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib (original) (raw)

Abstract

Many cases of hypereosinophilia, formerly classified as hypereosinophilic syndrome, can now be characterized as chronic eosinophilic leukemia (CEL) based on the demonstration of characteristic genetic markers indicating clonality of hematopoiesis. Here we report on a 33-year-old male patient with central nervous system manifestations of CEL and an excellent response to low-dose imatinib (Glivec). Molecular analysis demonstrated a constitutive activation of the platelet-derived growth factor receptor-alpha (PDGFR-A) as the mechanism of responsiveness to imatinib.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

BM:

Bone marrow

CEL:

Chronic eosinophilic leukemia

CML:

Chronic myeloid leukemia

CNS:

Central nervous system

HES:

Hypereosinophilic syndrome

FIP1L1:

FIP1-like gene

PB:

Peripheral blood

PDGFR-A/B:

Platelet-derived growth factor receptor-alpha/beta

References

  1. Chusid MJ, Dale DC, West BC, Wolff SM (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54:1–27
  2. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH (2002) Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359:1577–1578
    CAS PubMed Google Scholar
  3. Simon HU, Plotz SG, Dummer R, Blaser K (1999) Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341:1112–1120
    Article CAS PubMed Google Scholar
  4. Bain BJ (2003) Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. Br J Haematol 122:173–179
    Article PubMed Google Scholar
  5. Bain B, Pierre R, Imbert M, Vardiam JW, Brunning RD, Flandrin G (2001) Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. In: Jaffe E, Harris NL, Stein H, Vardiman JW (eds) World Health classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues, 1st edn. IARC Press, Lyon, pp 29–31
  6. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, et al. (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347:481–487
    Article CAS PubMed Google Scholar
  7. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, et al. (2002) Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 16:53–59
    Article CAS PubMed Google Scholar
  8. Cross NC, Feng L, Bungey J, Goldman JM (1993) Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction. Leuk Lymphoma 11 [Suppl 1]:39–43
    Google Scholar
  9. Cross NC, Melo JV, Feng L, Goldman JM (1994) An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 8:186–189
    CAS PubMed Google Scholar
  10. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201–1214
    Article CAS PubMed Google Scholar
  11. Longley BJ Jr, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ, et al. (1999) Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A 96:1609–1614
    Article CAS PubMed Google Scholar
  12. Goldman JM, Melo JV (2003) Chronic myeloid leukemia—advances in biology and new approaches to treatment. N Engl J Med 349:1451–1464
    Article CAS PubMed Google Scholar
  13. Cross NC, Reiter A (2002) Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 16:1207–1212
    Article CAS PubMed Google Scholar
  14. Macdonald D, Reiter A, Cross NC (2002) The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 107:101–107
    Article CAS PubMed Google Scholar
  15. Golub TR, Barker GF, Lovett M, Gilliland DG (1994) Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307–316
    CAS PubMed Google Scholar
  16. Steer EJ, Cross NC (2002) Myeloproliferative disorders with translocations of chromosome 5q31–35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 107:113–122
    Article CAS PubMed Google Scholar
  17. Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, et al. (2003) Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 101:4714–4716
    Article CAS PubMed Google Scholar
  18. Coutant G, Bletry O, Prin L, Hauteville D, de Puyfontaine O, Abgrall JF, et al. (1993) Treatment of hypereosinophilic syndromes of myeloproliferative expression with the combination of hydroxyurea and interferon alpha. Apropos of 7 cases. Ann Med Interne (Paris) 144:243–250
    Google Scholar
  19. Esteva-Lorenzo FJ, Meehan KR, Spitzer TR, Mazumder A (1996) Allogeneic bone marrow transplantation in a patient with hypereosinophilic syndrome. Am J Hematol 51:164–165
    Article CAS PubMed Google Scholar
  20. Juvonen E, Volin L, Koponen A, Ruutu T (2002) Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome. Bone Marrow Transplant 29:457–458
    Article CAS PubMed Google Scholar

Download references

Acknowledgements

We would like to thank PD Dr. Claudia Schoch, Munich and Dr. Schwab, Wiesbaden for performing cytogenetics, FISH, and PCR analysis to exclude classic CML.

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology, Dr.-Horst-Schmidt-Kliniken GmbH, Ludwig-Erhard-Str. 100, 65199, Wiesbaden, Germany
    Norbert Frickhofen & Bernd Jung
  2. Department of Rheumatology/Clinical Immunology/Nephrology, Dr.-Horst-Schmidt-Kliniken GmbH, Wiesbaden, Germany
    Elisabeth Märker-Hermann & Heidi Bauer
  3. III. Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Andreas Reiter, Christoph Walz & Andreas Hochhaus

Authors

  1. Norbert Frickhofen
    You can also search for this author inPubMed Google Scholar
  2. Elisabeth Märker-Hermann
    You can also search for this author inPubMed Google Scholar
  3. Andreas Reiter
    You can also search for this author inPubMed Google Scholar
  4. Christoph Walz
    You can also search for this author inPubMed Google Scholar
  5. Bernd Jung
    You can also search for this author inPubMed Google Scholar
  6. Heidi Bauer
    You can also search for this author inPubMed Google Scholar
  7. Andreas Hochhaus
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toNorbert Frickhofen.

Rights and permissions

About this article

Cite this article

Frickhofen, N., Märker-Hermann, E., Reiter, A. et al. Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib.Ann Hematol 83, 477–480 (2004). https://doi.org/10.1007/s00277-004-0845-z

Download citation

Keywords